ArticleJournal of the International Neuropsychological Society : JINS2021
Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease.
Article in Journal of the International Neuropsychological Society : JINS, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Driving among individuals with chronic conditions: A systematic review of applied research using kinematic driving sensors.Journal of the American Geriatrics Society · 2024Pooled it
- Demographically adjusted norms for a French-Quebec version of the face-name associative recognition test.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2026Article
- Smartphone-based detection of subtle memory decline in prodromal Alzheimer's disease.NPJ digital medicine · 2026Article
- The Role of Clinical, Plasma, and Imaging Biomarkers in Assessing Future Dementia Risk in Individuals With Subjective Cognitive Decline.Neurology · 2026Observational
- Cognitive Trajectories from Preclinical Alzheimer's Disease to Dementia.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Differential cued recall memory impairment in mild cognitive impairment due to Alzheimer's disease versus Parkinson's disease.Journal of neuropsychology · 2026Article
- Diagnostic performance of verbal fluency measures: a cross-sectional study in the stages of cognitive continuum.Alzheimer's research & therapy · 2026Article
- Neuroinflammation PET and long-term cognition and survival in symptomatic Alzheimer's disease.Alzheimer's research & therapy · 2025Article
- Recent Advances and Future Directions in Alzheimer's Disease Genetic Research.International journal of molecular sciences · 2025Review
- Disease stage-specific atrophy markers in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Perceptual discrimination of complex objects: Apolipoprotein E e4 gene-dose effects in mid-life.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Smartphone- and Tablet-Based Tools to Assess Cognition in Individuals With Preclinical Alzheimer Disease and Mild Cognitive Impairment: Scoping Review.Journal of medical Internet research · 2025Article
- Synaptic protein CSF levels relate to memory scores in individuals without dementia.Alzheimer's research & therapy · 2025Article
- Alzheimer's disease plasma biomarkers and physical functioning in a diverse sample of adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The financial consequences of undiagnosed memory disorders.Journal of financial economics · 2024Article
- Digital cognitive assessments as low-burden markers for predicting future cognitive decline and tau accumulation across the Alzheimer's spectrum.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Automated deep learning segmentation of neuritic plaques and neurofibrillary tangles in Alzheimer disease brain sections using a proprietary software.Journal of neuropathology and experimental neurology · 2024Article
- Synaptic protein CSF levels relate to memory scores in individuals without dementia.Research square · 2024Article
- Prediction of Mild Cognitive Impairment Status: Pilot Study of Machine Learning Models Based on Longitudinal Data From Fitness Trackers.JMIR formative research · 2024Article
- Cognitive and Functional Change Over Time in Cognitively Healthy Individuals According to Alzheimer Disease Biomarker-Defined Subgroups.Neurology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
objectiveAlzheimer's disease (AD) studies are increasingly targeting earlier (pre)clinical populations, in which the expected degree of observable cognitive decline over a certain time interval is reduced as compared to the dementia stage. Consequently, endpoints to capture early cognitive changes require refinement. We aimed to determine the sensitivity to decline of widely applied neuropsychological tests at different clinical stages of AD as outlined in the National Institute on Aging - Alzheimer's Association (NIA-AA) research framework.
methodAmyloid-positive individuals (as determined by positron emission tomography or cerebrospinal fluid) with longitudinal neuropsychological assessments available were included from four well-defined study cohorts and subsequently classified among the NIA-AA stages. For each stage, we investigated the sensitivity to decline of 17 individual neuropsychological tests using linear mixed models.
results1103 participants (age = 70.54 ± 8.7, 47% female) were included: n = 120 Stage 1, n = 206 Stage 2, n = 467 Stage 3 and n = 309 Stage 4. Neuropsychological tests were differentially sensitive to decline across stages. For example, Category Fluency captured significant 1-year decline as early as Stage 1 (β = -.58, p < .001). Word List Delayed Recall (β = -.22, p < .05) and Trail Making Test (β = 6.2, p < .05) became sensitive to 1-year decline in Stage 2, whereas the Mini-Mental State Examination did not capture 1-year decline until Stage 3 (β = -1.13, p < .001) and 4 (β = -2.23, p < .001).
conclusionsWe demonstrated that commonly used neuropsychological tests differ in their ability to capture decline depending on clinical stage within the AD continuum (preclinical to dementia). This implies that stage-specific cognitive endpoints are needed to accurately assess disease progression and increase the chance of successful treatment evaluation in AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.